Hui Lyu

1.3k total citations
33 papers, 998 citations indexed

About

Hui Lyu is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Hui Lyu has authored 33 papers receiving a total of 998 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 17 papers in Oncology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Hui Lyu's work include HER2/EGFR in Cancer Research (13 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Histone Deacetylase Inhibitors Research (5 papers). Hui Lyu is often cited by papers focused on HER2/EGFR in Cancer Research (13 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Histone Deacetylase Inhibitors Research (5 papers). Hui Lyu collaborates with scholars based in China, United States and South Korea. Hui Lyu's co-authors include Bolin Liu, Jingcao Huang, Jian Ma, Zhimin He, Jianxiang Wang, Shuiliang Wang, Shuang Liu, Ying Wu, Yong Song and Xuefei Shi and has published in prestigious journals such as Nature Communications, Cancer Research and Scientific Reports.

In The Last Decade

Hui Lyu

33 papers receiving 991 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hui Lyu China 16 641 469 282 223 128 33 998
Samuel W. Brady United States 14 608 0.9× 588 1.3× 187 0.7× 190 0.9× 188 1.5× 25 1.1k
Ainura Kyshtoobayeva United States 13 441 0.7× 420 0.9× 192 0.7× 169 0.8× 95 0.7× 18 859
Justine Y. Bruce United States 16 413 0.6× 329 0.7× 175 0.6× 129 0.6× 275 2.1× 73 955
Lorenzo Castagnoli Italy 17 368 0.6× 406 0.9× 169 0.6× 120 0.5× 105 0.8× 31 726
Jay Overholser United States 11 439 0.7× 358 0.8× 157 0.6× 138 0.6× 117 0.9× 16 767
Erika Yorida Canada 13 728 1.1× 513 1.1× 231 0.8× 135 0.6× 204 1.6× 14 1.2k
Rosalin Mishra United States 11 421 0.7× 345 0.7× 81 0.3× 131 0.6× 139 1.1× 20 724
Ulla Kasten-Pisula Germany 15 538 0.8× 389 0.8× 197 0.7× 145 0.7× 300 2.3× 17 883
Shane K. Green Canada 7 462 0.7× 378 0.8× 233 0.8× 63 0.3× 117 0.9× 9 795
Cenap Güngör Germany 19 544 0.8× 393 0.8× 164 0.6× 80 0.4× 108 0.8× 51 941

Countries citing papers authored by Hui Lyu

Since Specialization
Citations

This map shows the geographic impact of Hui Lyu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hui Lyu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hui Lyu more than expected).

Fields of papers citing papers by Hui Lyu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hui Lyu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hui Lyu. The network helps show where Hui Lyu may publish in the future.

Co-authorship network of co-authors of Hui Lyu

This figure shows the co-authorship network connecting the top 25 collaborators of Hui Lyu. A scholar is included among the top collaborators of Hui Lyu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hui Lyu. Hui Lyu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lyu, Hui, et al.. (2023). HER3 targeting augments the efficacy of panobinostat in claudin-low triple-negative breast cancer cells. npj Precision Oncology. 7(1). 72–72. 11 indexed citations
2.
Liu, Hao, et al.. (2023). Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo. Biological Procedures Online. 25(1). 19–19. 6 indexed citations
3.
4.
Lyu, Hui, Fei Shen, Sanbao Ruan, et al.. (2023). HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel. Cancer Cell International. 23(1). 204–204. 7 indexed citations
5.
Wang, Ping, Huixian Li, Hui Wang, et al.. (2023). Risk factors and early markers for echovirus type 11 associated haemorrhage-hepatitis syndrome in neonates, a retrospective cohort study. Frontiers in Pediatrics. 11. 1063558–1063558. 9 indexed citations
6.
Lyu, Hui, Guanmin Jiang, Sanbao Ruan, et al.. (2022). ALKBH5-Mediated m6A Demethylation of GLUT4 mRNA Promotes Glycolysis and Resistance to HER2-Targeted Therapy in Breast Cancer. Cancer Research. 82(21). 3974–3986. 72 indexed citations
7.
Luo, Liyun, Zhijie Zhang, Ni Qiu, et al.. (2021). Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer. Nature Communications. 12(1). 2699–2699. 67 indexed citations
8.
Pan, Wei, Hui Lyu, Zhangping Yu, et al.. (2021). Validation of a six-item dietary calcium screening tool among HIV patients in China. Public Health Nutrition. 24(15). 4786–4795. 1 indexed citations
9.
Liu, Shuang, Sanbao Ruan, Hui Lyu, et al.. (2021). Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC. Molecular Therapy — Oncolytics. 21. 303–314. 14 indexed citations
10.
Liu, Xiaolong, Shuang Liu, Hui Lyu, et al.. (2019). Development of Effective Therapeutics Targeting HER3 for Cancer Treatment. Biological Procedures Online. 21(1). 5–5. 48 indexed citations
11.
Lyu, Hui, et al.. (2018). Understanding the biology of HER3 receptor as a therapeutic target in human cancer. Acta Pharmaceutica Sinica B. 8(4). 503–510. 91 indexed citations
12.
Lyu, Hui, Jingcao Huang, Zhimin He, & Bolin Liu. (2018). Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells. Biological Procedures Online. 20(1). 16–16. 12 indexed citations
13.
Lyu, Hui, Jingcao Huang, Zhimin He, & Bolin Liu. (2018). Epigenetic mechanism of survivin dysregulation in human cancer. Science China Life Sciences. 61(7). 808–814. 31 indexed citations
14.
Wu, Ying, Hui Lyu, Hongbing Liu, et al.. (2016). Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer. Scientific Reports. 6(1). 31093–31093. 100 indexed citations
15.
Lyu, Hui, Jingcao Huang, Susan M. Edgerton, et al.. (2015). Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.. PubMed. 8(6). 6143–56. 10 indexed citations
16.
Su, Heng, et al.. (2015). Protective Effects of Bifidobacterium on intestinal tissue of newborn rats with necrotizing enterocolitis and its regulation. Zhonghua weichan yixue zazhi. 18(4). 290–295. 1 indexed citations
17.
Huang, Jingcao, Hui Lyu, Jianxiang Wang, & Bolin Liu. (2015). Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia. Cancer Letters. 366(2). 160–172. 28 indexed citations
18.
Ma, Jian, Hui Lyu, Jingcao Huang, & Bolin Liu. (2014). Targeting of erbB3 receptor to overcome resistance in cancer treatment. Molecular Cancer. 13(1). 105–105. 143 indexed citations
19.
Wang, Shuiliang, Jingcao Huang, Hui Lyu, et al.. (2013). Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Research. 15(5). R101–R101. 42 indexed citations
20.
Huang, Jingcao, Shuiliang Wang, Hui Lyu, et al.. (2013). The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. Molecular Cancer. 12(1). 134–134. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samuel W. Brady Breakdown of academic impact, for papers by Ainura Kyshtoobayeva Breakdown of academic impact, for papers by Justine Y. Bruce Breakdown of academic impact, for papers by Lorenzo Castagnoli Breakdown of academic impact, for papers by Jay Overholser Breakdown of academic impact, for papers by Erika Yorida Breakdown of academic impact, for papers by Rosalin Mishra Breakdown of academic impact, for papers by Ulla Kasten-Pisula Breakdown of academic impact, for papers by Shane K. Green Breakdown of academic impact, for papers by Cenap Güngör
Rankless by CCL
2026